Suven Life Sciences (BOM:530239) ROCE %: -30.02% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530239 Suven Life Sciences Ltd BOM:530239
41 GF Score
Price ₹306.30
GF Value ₹97.20
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Suven Life Sciences ROCE %?

Suven Life Sciences BOM:530239 +2.24% 41 ROCE % is -30.02% as of Mar. 2026. GuruFocus rates BOM:530239 with a GF Score™ of 41/100 and a GF Value™ of ₹97.20 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Suven Life Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -30.02%.

Suven Life Sciences  (BOM:530239) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Suven Life Sciences ROCE % Related Terms

Suven Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Suven Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suven Life Sciences ROCE % Chart

Suven Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -114.46 -49.42 -32.63 -83.90 -77.02

Suven Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -157.37 -184.49 -109.28 -144.07 -30.02
BOM:530239
41GF Score
Suven Life Sciences Ltd BOM:530239
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suven Life Sciences ROCE % Calculation

Suven Life Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-2761.863/( ( (1351.833 - 234.86) + (6242.14 - 187.52) )/ 2 )
=-2761.863/( (1116.973+6054.62)/ 2 )
=-2761.863/3585.7965
=-77.02 %

Suven Life Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-1817.508/( ( (0 - 0) + (6242.14 - 187.52) )/ 1 )
=-1817.508/( ( 0 + 6054.62 )/ 1 )
=-1817.508/6054.62
=-30.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -30.02% mean?
Suven Life Sciences (BOM:530239) has a ROCE % of -30.02% as of Mar. 2026.
Is Suven Life Sciences' ROCE % too high?
Suven Life Sciences' current ROCE % is -30.02%. Overall, Suven Life Sciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' ROCE % compare to ZTS?
Suven Life Sciences' ROCE % of -30.02% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suven Life Sciences's current ROCE % is -30.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (BOM:530239) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹97.20, compared to a current price of ₹306.30 — trading 215.1% above its estimated fair value. The current ROCE % is -30.02%. Suven Life Sciences' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Suven Life Sciences (BOM:530239), the current ROCE % is -30.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suven Life Sciences (BOM:530239) Overvalued in 2026?

Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued. The current stock price of ₹306.30 is trading 215.1% above its estimated GF Value™ of ₹97.20. GuruFocus considers Suven Life Sciences to be Significantly Overvalued.

Key valuation signals for BOM:530239:

  • ROCE %: -30.02%
  • GF Value™: ₹97.20 vs. price of ₹306.30 (215.1% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Suven Life Sciences Business Description

Other Exchanges SUVEN:India
Address Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
41GF Score

Get the complete analysis for BOM:530239

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹306.30
Price
₹97.20
GF Value